logo

ranolazine - RANEXA®

Disclaimer - Please see package insert for additional information and possible updates. The authors make no claims of the accuracy of the information contained herein; and these suggested doses are not a substitute for clinical judgment. Neither GlobalRPh Inc. nor any other party involved in the preparation of this program shall be liable for any special, consequential, or exemplary damages resulting in whole or part from any user's use of or reliance upon this material. PLEASE READ THE DISCLAIMER CAREFULLY BEFORE ACCESSING OR USING THIS SITE. BY ACCESSING OR USING THIS SITE, YOU AGREE TO BE BOUND BY THE TERMS AND CONDITIONS SET FORTH IN THE DISCLAIMER.   Read the disclaimer
>  NEW DRUG - INDEX PAGE
CLINICAL PHARMACOLOGY -
Mechanism of Action
------------------------
The mechanism of action of ranolazine's antianginal effects has not been determined. Ranolazine has anti-ischemic and antianginal effects that do not depend upon reductions in heart rate or blood pressure. It does not affect the rate-pressure product, a measure of myocardial work, at maximal exercise. Ranolazine at therapeutic levels can inhibit the cardiac late sodium current (INa). However, the relationship of this inhibition to angina symptoms is uncertain.


INDICATIONS AND USAGE
----------------
Ranexa is indicated for the treatment of chronic angina.



DOSAGE AND ADMINISTRATION
-------------------
500 mg twice daily and increase to 1000 mg twice daily, based on clinical symptoms.


DOSAGE FORMS AND STRENGTHS
------------------
Extended-release tablets: 500 mg, 1000

top of page

REFERENCE

Package Insert data
more Career Center image description
Medical Calculators - A thru Z
Lab Values - A thru Z